DexCom, Inc. $DXCM Holdings Lifted by Geode Capital Management LLC

Geode Capital Management LLC increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,006,183 shares of the medical device company’s stock after buying an additional 42,411 shares during the quarter. Geode Capital Management LLC’s holdings in DexCom were worth $727,842,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of DXCM. Holocene Advisors LP purchased a new position in shares of DexCom during the third quarter valued at $163,964,000. CIBC Private Wealth Group LLC grew its holdings in shares of DexCom by 374.3% during the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock valued at $195,666,000 after buying an additional 2,294,709 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of DexCom by 2.3% during the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after buying an additional 1,133,638 shares in the last quarter. Intermede Investment Partners Ltd purchased a new position in shares of DexCom during the fourth quarter valued at $60,351,000. Finally, Iron Triangle Partners LP purchased a new position in shares of DexCom during the third quarter valued at $57,196,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, insider Kevin R. Sayer sold 26,759 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the sale, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This represents a 3.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,871 shares of company stock valued at $2,306,638 over the last quarter. Insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on DXCM shares. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Sanford C. Bernstein set a $77.00 target price on DexCom in a research note on Friday, May 1st. Raymond James Financial set a $81.00 target price on DexCom in a research note on Friday, May 1st. Wells Fargo & Company lowered their target price on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Finally, Mizuho set a $75.00 target price on DexCom in a research note on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $82.42.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $73.74 on Friday. The business’s 50-day moving average price is $64.17 and its two-hundred day moving average price is $66.44. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company has a market capitalization of $28.45 billion, a P/E ratio of 31.51, a price-to-earnings-growth ratio of 1.22 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the company posted $0.32 earnings per share. The business’s quarterly revenue was up 15.0% compared to the same quarter last year. Analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.